TrianglePUBLICATIONS · 39162872
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Gastric Cancer
- Publication date
- 2024 Nov
- First author
- Boku N
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Boku N
- type
- Author
- name
- Omori T
- type
- Author
- name
- Shitara K
- type
- Author
- name
- Sakuramoto S
- type
- Author
- name
- Yamaguchi K
- type
- Author
- name
- Kato K
- type
- Author
- name
- Kadowaki S
- type
- Author
- name
- Tsuji K
- type
- Author
- name
- Ryu MH
- type
- Author
- name
- Oh DY
- type
- Author
- name
- Oh SC
- type
- Author
- name
- Rha SY
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Boku N
- type
- Author
- name
- Omori T
- type
- Author
- name
- Shitara K
- type
- Author
- name
- Sakuramoto S
- type
- Author
- name
- Yamaguchi K
- type
- Author
- name
- Kato K
- type
- Author
- name
- Kadowaki S
- type
- Author
- name
- Tsuji K
- type
- Author
- name
- Ryu MH
- type
- Author
- name
- Oh DY
- type
- Author
- name
- Oh SC
- type
- Author
- name
- Rha SY
- type
- Author
- bibliography ids
- nci-bib-98f491ca2c21a26e7a1a86a5
- book metadata
- content sha256
- 9f3043c8f6d0bae54b3ebbfe902709003af69456be59a30fbf213704355ae032
- document type
- citation
- dois
- 10.1007/s10120-024-01535-0
- electronic publication date
- display
- 2024 Aug 20
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:39162872
- immutable id
- pubmed:39162872@9f3043c8f6d0bae54b3ebbfe902709003af69456be59a30fbf213704355ae032
- journal
- abbreviation
- Gastric Cancer
- issn electronic
- 1436-3305
- issn print
- 1436-3291
- issue
- 6
- name
- Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
- nlm unique id
- 100886238
- pages
- 1287-1301
- volume
- 27
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 39162872
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- 162b0fc9ea7cb403bc24d007e9a11756acaca879d78d20e3e84165b38edfa6b7
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Nov
- precision
- month
- year
- 2024
- publication types
- Journal Article
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Preserved source evidence · Not medical advice